+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019

  • ID: 4900232
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 81 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AfaSci Inc
  • Aptarion biotech AG
  • Eli Lilly and Co
  • H. Lundbeck AS
  • Nepsone ehf
  • Pharmnovo AB
  • MORE
Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019

Summary

According to the recently published report 'Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019'; Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 9 molecules.

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception.

The report 'Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019' outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 2, 1, 4 and 2 respectively. Report covers products from therapy areas Central Nervous System and Immunology which include indications Migraine, Cluster Headache Syndrome (Cluster Headache), Dental Pain (Toothache/Tooth Pain), Fibromyalgia (Fibromyalgia Syndrome), Inflammatory Pain, Osteoarthritis Pain, Pain, Psoriasis and Traumatic Pain.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
  • The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AfaSci Inc
  • Aptarion biotech AG
  • Eli Lilly and Co
  • H. Lundbeck AS
  • Nepsone ehf
  • Pharmnovo AB
  • MORE
Introduction
Report Coverage
Calcitonin Gene Related Peptide (CGRP) - Overview
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
AfaSci Inc
Aptarion biotech AG
Eli Lilly and Co
H. Lundbeck AS
Living Cell Technologies Ltd
Nepsone ehf
Pharmnovo AB
Serometrix LLC
Teva Pharmaceutical Industries Ltd
Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
AFAP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eptinezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXL-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide (CGRP) - Dormant Products
Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
Featured News & Press Releases
Oct 24, 2019: Teva to present new analyses of fremanezumab and country-specific burden of migraine at 24th World Congress of Neurology
Oct 02, 2019: EMGALITY (galcanezumab) now available in Canada for preventive treatment of migraine
Sep 05, 2019: Alder BioPharmaceuticals to Showcase Eptinezumab Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society
Sep 05, 2019: Lilly’s migraine treatment Emgality lands in Korea
Sep 03, 2019: Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society
Aug 21, 2019: Fremanezumab data in The Lancet demonstrate clinically meaningful reduction in monthly migraine days versus Placebo for patients with difficult-to-treat migraine
Aug 06, 2019: Lilly reports positive data from CONQUER study of Emgality
Jul 15, 2019: Lilly’s Emgality shows favourable profile in Phase III studies
Jul 11, 2019: New England Journal of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache
Jul 11, 2019: Alder BioPharmaceuticals presents new data on migraine-free months, migraine severity and quality of life, demonstrating eptinezumab’s clinical profile for migraine prevention
Jul 10, 2019: Teva to present new data on AJOVY (fremanezumab-vfrm) injection at the American Headache Society’s 61st Annual Scientific Meeting
Jul 09, 2019: Teva's Fremanezumab improves migraine-related disorders, quality of life
Jul 08, 2019: Alder BioPharmaceuticals to showcase 14 new data presentations demonstrating Eptinezumab's migraine prevention and quality of life impact at American Headache Society Meeting
Jul 04, 2019: Teva reports positive data from fremanezumab’s migraine trial
Jun 19, 2019: Alder BioPharmaceuticals to webcast upcoming breakfast symposium with key opinion leaders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AfaSci Inc, H2 2019
Pipeline by Aptarion biotech AG, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by H. Lundbeck AS, H2 2019
Pipeline by Living Cell Technologies Ltd, H2 2019
Pipeline by Nepsone ehf, H2 2019
Pipeline by Pharmnovo AB, H2 2019
Pipeline by Serometrix LLC, H2 2019
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AfaSci Inc
  • Aptarion biotech AG
  • Eli Lilly and Co
  • H. Lundbeck AS
  • Living Cell Technologies Ltd
  • Nepsone ehf
  • Pharmnovo AB
  • Serometrix LLC
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
Adroll
adroll